CELATOR PHARMACEUTICALS INC (CPXX) financial statements (2020 and earlier)

Company profile

Business Address 303B COLLEGE ROAD EAST
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments233224
Cash and cash equivalents233224
Restricted cash and investments00 
Receivables  1
Assets held-for-sale0
Other undisclosed current assets111
Total current assets:243426
Noncurrent Assets
Property, plant and equipment111
Deferred costs 1 
Other noncurrent assets010
Other undisclosed noncurrent assets (1) 
Total noncurrent assets:121
TOTAL ASSETS:263527
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities343
Accounts payable111
Accrued liabilities222
Employee-related liabilities 1 
Interest and dividends payable 0 
Debt50 
Deferred revenue and credits011
Other undisclosed current liabilities (1) 
Total current liabilities:933
Noncurrent Liabilities
Long-term debt and lease obligation 10 
Long-term debt, excluding current maturities 10 
Liabilities, other than long-term debt101
Deferred revenue and credits 01
Other liabilities1  
Other undisclosed noncurrent liabilities900
Total noncurrent liabilities:11101
Total liabilities:19134
Stockholders' equity
Stockholders' equity attributable to parent, including:72223
Common stock000
Additional paid in capital175171156
Accumulated other comprehensive loss(1)(1)(1)
Accumulated deficit(169)(149) 
Warrants and rights outstanding111
Other undisclosed stockholders' equity attributable to parent  (132)
Total stockholders' equity:72223
TOTAL LIABILITIES AND EQUITY:263527

Income statement (P&L) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
Operating expenses(20)(19)(15)
Other undisclosed operating income121
Operating loss:(18)(18)(15)
Nonoperating income (expense)
(Foreign Currency Transaction loss, before Tax)
(0)(0)(0)
Interest and debt expense(2)(1)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes00(7)
Loss from continuing operations before income taxes:(20)(19)(22)
Income tax benefit121
Net loss available to common stockholders, diluted:(19)(17)(21)

Comprehensive Income ($ in millions)

12/31/2015
12/31/2014
12/31/2013
Net loss:(19)(17)(21)
Comprehensive loss, net of tax, attributable to parent:(19)(17)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: